Anvisa Says Retatrutida Is Unapproved as Illegal Versions Spread

Overview

• Anvisa issued a public alert on July 24 that retatrutida remains experimental, is not authorized for sale in any country, and should not be used.
• The agency said Eli Lilly has not filed for regulatory approval and is completing clinical studies before any registration request can be made.
• Products offered online or seized at borders and events have been marketed as retatrutida but are illegal and may not contain the drug or may carry contaminants.
• Clinical results have shown large weight losses in trials — a Lancet study reported up to 28.3% average weight reduction at the highest dose — but safety, proper dosing, and long‑term data are not yet complete.
• Consumers face health risks from wrong dose, impurities, lack of sterility or poor storage and should avoid buying unregistered injections while regulators continue seizures and enforcement.